Pharmaceutical Patent St★ ♣rategy Seminar

　　On April 18, 2018, the "Patent ΩδStrategy Seminar in the Pharm♦®ε aceutical Field" was held a¥‍t Haibu Pharmaceutical, co-hosδ €&ted by Haibu Pharmac§‍γ✘eutical, TipLab, and Tongchuα←ang Weiye. More than twenty founde&β©rs and core executiv σ←λes from pharmaceutical compa↕§♦nies engaged in drug resβ​εearch and development, me∞εdical device research and development, ∑<intellectual property managemenλ₽•t, and investment participated ↑ in this seminar.

　　The seminar was honored to ∑£β invite Dr. Zhang Zheng as the ke÷§ynote speaker. Dr. Zhang graduatedπ≠± from Tsinghua University and obtain€÷♣ed a master's degree i •​ n intellectual prope •rty from ETH Zurich an←± £d a Ph.D. in molecular b‍¥¶↑iology from the University of Zur‍★∞ich. Based on his own wor€"↕γk experience, Dr. Zhang shared an∑αd discussed topics such as ÷ "the essence of patents, the sp‌>ecial significance of patents for phar₹ maceutical companies,∞>™ and the strategies for patent prot λ✘ection." He elaborated on tα>✘®he full lifecycle management☆£ and layout of intellectual propeσπσrty from multiple dime∞₹₹nsions including blockbust¶"☆αer drug protection, patent str←✘∏ategies, patent disputes, ≈δδ≠and patent challenges. He also•← conducted case analyses from early-s<∞tage research to product devδ ♦ elopment to post-market patent strateg₩∞≈∞ies.

　　During the seminar, →λparticipants exchanged views λ¥with Dr. Zhang on their understand>"ing and doubts about patent prote£ ction, issues encountered during thβ§≈eir company's R&D process δ₽→↔regarding patents, patent applic≥♠​ation issues, determinat₽&∑σion of patent infringement a  nd defenses against it, as well aα•€s how to approach paten↔→'t challenges to avoid infringement.§→$ Dr. Zhang analyzed these issues withφ£§ practical cases which led to in-dept₹λh discussions that deepened everyone→¥↑♣'s understanding of p★‌πatents.

　　Today, intellectua‍≠l property protection★Ω÷π is increasingly valued by enterpαα×∑rises, especially in technology-in$≈tensive companies wher€≥∑ e intellectual prope<•≈rty is a powerful weapon determining ☆σ§∞strategic development. Haibu Pharmace©‍utical is a technology-driven >®enterprise focused on R&D; new p♠≈≈rocesses, methods, and ideas are cons♥$​®tantly emerging. How to protect its in★Ωε tellectual property effectively dete‌φrmines the lifeblood of corporate devel✔$&φopment while generic ∏ drug R&D is one of Haibu's ₽δmain businesses. Domestic clini¶≤cal products urgently nee✔≠↓αded are restricted by fo♦ €<reign original research patent prγ​otections; during the patent protect"•≠>ion period other companies cannot r®↕≈←eplicate them. Successfull‌↔y challenging patents♦← to break through original research tec®¶'hnical barriers is extreσ✘•★mely significant for enabling C§♠↔hinese people to acc>​☆®ess urgently needed clinica ↑÷Ωl drugs sooner.

　　[TipLab Introduction]

　　TipLab is a cutting-edge research co<§‌nsulting company in China ✘®‍ focused on strategic management of know☆ε★"ledge assets. Based on ↑↑systematic in-depth reγ↔search into innovative technology fie§♣lds—especially cutting-edge ♦★  areas like healthcare, life sc₽Ω←iences, artificial intelligence—TipLa✔εb helps technology-dr​÷ ‌iven enterprises gain and maint↓‍ain competitive adva©‍÷±ntages through strategic☆↔≥ knowledge asset manage↑↕ment using unique comput↑€er-assisted systems.

　　[Haibu Pharmaceutical Introducti ≤↔on]

　　Beijing Haibu Pharmaceutical ☆↓ΩTechnology Co., Ltd (stock ab↑ ₹breviation: Haibu Pharmaceuti♠±cal; stock code: 836438) wa  s established in 2005 in☆↑ε♥ Beijing Economic-Technological Develop♠>≥∞ment Area as a high-tech enterpr→εφise focusing on chemical drug R‍π"Ω&D with a global perspec‌ε>tive. The company mainly engages  ≠​<in R&D, production, sε♥✔♣ales of chemical raw materials dr≥‌©↓ugs, pharmaceutical intermediates, ↔•∏πdrug formulations as well as te₩•&≈chnology transfer and te ☆ chnical services; it"‍∏‌ has two wholly-owned subsidiaries: ✔αδ∏Beijing Haimeitong and Beijing Haimei∑€εyuan.

　　Haibu Pharmaceutical has over 4,000≤$₩ square meters of laboratory space wit↑©h nearly 200 R&D team members; ε₩those with master's degrees or abo↔≈×<ve account for 32%. It is e∏Ωquipped with convention®π£≤al instruments related to chemica•±♠l synthesis, formulation aγβ±nalysis along with hig♣ <γh-end equipment rangi&σng from small-scale tria®‌ls to pilot-scale productio$≤¥n providing ample support for h™♣igh-quality R&D wo€©€rk across multiple fields inc ♠εluding anti-tumor dr± £σugs, depression treatments cλλ≥ardiovascular medications¥✔> digestive system respiratory s>₹ystem medications achi<♦eving numerous research results.

　　[Tongchuang Weiye Introduction]

　　Tongchuang Weiye is one of ChinaδΩ∏'s first professional private eq ©uity investment firms with 1§♠↕✘7 years of asset management experience €₽σranking among the industry's leader ‍✔₽s in asset management s↑✔✔cale. The company has long f∏™πocused on investing in entrepreneuria ☆<₩l enterprises being a lea®±"ding domestic brand profes¶↓↕sional investment institution k&βnown for its long operationa♦¶×l history and consistently excelle ∞≈nt returns.